Congenital hypothalamic hamartoma syndrome
MONDO:0009436Hypothalamic hamartomas (HH) are rare, tumor-like malformations that occur during fetal development and are present at birth. The lesions usually do not change in size or spread to other locations. Both the type and severity of symptoms vary greatly among patients with hypothalamic hamartomas. Common symptoms include frequent gelastic seizures (spontaneous laughing, giggling and/or smirking) or dacrystic seizures (crying or grunting); developmental delays; and/or precocious puberty. Additional symptoms may include cognitive impairment; emotional and behavioral difficulties; and endocrine disturbances. These symptoms often start early in life but are frequently misdiagnosed. For some patients, endocrine (hormonal) disturbances such as central precocious puberty may be the only symptom. These patients can often be treated successfully with medications. For some, however, HH can be disabling. For those with HH and epilepsy, it is common for the disorder to progress and for different types of seizures to develop. The seizures associated with HH often cannot be well-controlled with the standard seizure medications. For some, additional treatment such as surgical removal, radiosurgery, or thermoablation may be indicated. Though hypothalamic hamartomas can occur in patients with certain genetic disorders (such as Pallister-Hall syndrome), the majority of cases are sporadic.
Also known as: Pallister-Hall-like syndrome, congenital hypothalamic hamartoma syndrome, hamartoma of hypothalamus, hypothalamic hamartoma, hypothalamic hamartomas, hamartoma of the hypothalamus
47 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New pill aims to shield stomachs from common painkiller damage
Prevention Not yet recruitingThis study tests whether a new medicine called Fexuprazan (Fexuclue) can prevent stomach ulcers caused by NSAID painkillers like ibuprofen. About 360 adults with joint or muscle pain who need daily NSAIDs will take either Fexuprazan or an older drug (Lansoprazole) for 24 weeks. T…
Phase: PHASE4 • Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Prevention
Last updated Jun 27, 2026 12:07 UTC
-
Can your own blood and fat heal aching joints? new trial aims to find out
Symptom relief Not yet recruitingThis early-phase trial will test four orthobiologic treatments—PRP, bone marrow concentrate, hyaluronic acid, and nanofat—in 300 adults with various muscle, joint, tendon, or bone conditions. The goal is to see if these natural substances can reduce pain and improve joint functio…
Phase: EARLY_PHASE1 • Sponsor: PROREGEN • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Phone app may boost exercise for aching joints
Symptom relief Not yet recruitingThis study looks at whether a mobile app can help people with common pains (neck, shoulder, back, or knee) do their prescribed home exercises more regularly. About 30 adults will be split into two groups: one using the app and one doing traditional exercises. The goal is to see i…
Phase: NA • Sponsor: National Yang Ming Chiao Tung University • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New urdu tool could help millions with muscle and joint pain
Knowledge-focused Not yet recruitingThis study aims to translate and adapt a widely used questionnaire for musculoskeletal problems into Urdu. Researchers will enroll 110 Urdu-speaking adults, including patients with muscle or joint issues and healthy volunteers. The goal is to create a validated tool to measure sy…
Sponsor: Riphah International University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
AI vs. doctor: which note do patients trust more?
Knowledge-focused Not yet recruitingThis study looks at how patients feel when reading their own medical notes. Some will read the original doctor's note, others will read a simpler version written by artificial intelligence. Researchers want to see if the AI summary changes how much patients trust their doctor or …
Phase: NA • Sponsor: University of Texas at Austin • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New digital tool aims to speed up return to work for those with muscle pain
Knowledge-focused Not yet recruitingThis study tests a decision support system called SmaRTWork to help people on sick leave due to muscle or back pain return to work. About 298 adults in Norway will either use the system or receive usual care. The main goal is to see if the tool helps them return to work sustainab…
Phase: NA • Sponsor: Norwegian University of Science and Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC